losartan has been researched along with Cancer of Pancreas in 15 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 5.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| "Angiotensin II (AngII), the principal hormone of the renin-angiotensin system, is actively generated in the pancreas and has been proposed as a key mediator of inflammation." | 3.75 | Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. ( Arafat, HA; Aziz, T; Chehl, N; Chipitsyna, G; Gong, Q; Yeo, CJ, 2009) |
| "Patients with locally advanced pancreatic cancer have historically poor outcomes." | 2.90 | Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. ( Allen, JN; Baglini, CV; Berger, DL; Blaszkowsky, LS; Boucher, Y; Clark, JW; Corcoran, RB; DeLaney, TF; Drapek, LC; Duda, DG; Faris, JE; Fernández-Del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Jain, RK; Jiang, W; Kwak, EL; Lillemoe, KD; Ly, L; Murphy, JE; Nipp, RD; Parikh, AR; Qadan, M; Ryan, DP; Talele, N; Ting, DT; Weekes, CD; Wo, JY; Yeap, BY; Zhu, AX, 2019) |
| "On murine models of pancreatic cancer, Los NB shows a greater ability to remodel the tumor microenvironment than free losartan, including stromal depletion, vessel perfusion increase, and hypoxia relief." | 1.72 | Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. ( Bian, S; Chen, J; Dong, H; Jia, X; Li, Z; Qiu, N; Song, P; Song, W; Wang, H; Zhao, L; Zheng, S; Zhu, X, 2022) |
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 1.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| "Pancreatic cancer is one of the leading causes of cancer death, and represents a challenging chemotherapeutic problem." | 1.35 | Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. ( Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, S | 1 |
| Dong, H | 1 |
| Zhao, L | 1 |
| Li, Z | 2 |
| Chen, J | 1 |
| Zhu, X | 1 |
| Qiu, N | 1 |
| Jia, X | 1 |
| Song, W | 1 |
| Zheng, S | 1 |
| Wang, H | 1 |
| Song, P | 1 |
| Boucher, Y | 4 |
| Posada, JM | 1 |
| Subudhi, S | 1 |
| Kumar, AS | 1 |
| Rosario, SR | 1 |
| Gu, L | 1 |
| Kumra, H | 1 |
| Mino-Kenudson, M | 1 |
| Talele, NP | 1 |
| Duda, DG | 2 |
| Fukumura, D | 1 |
| Wo, JY | 2 |
| Clark, JW | 2 |
| Ryan, DP | 2 |
| Fernandez-Del Castillo, C | 2 |
| Hong, TS | 2 |
| Pittet, MJ | 1 |
| Jain, RK | 4 |
| Murphy, JE | 1 |
| Jiang, W | 1 |
| Yeap, BY | 1 |
| Drapek, LC | 1 |
| Ly, L | 1 |
| Baglini, CV | 1 |
| Blaszkowsky, LS | 1 |
| Ferrone, CR | 1 |
| Parikh, AR | 1 |
| Weekes, CD | 1 |
| Nipp, RD | 1 |
| Kwak, EL | 1 |
| Allen, JN | 1 |
| Corcoran, RB | 1 |
| Ting, DT | 1 |
| Faris, JE | 1 |
| Zhu, AX | 1 |
| Goyal, L | 1 |
| Berger, DL | 1 |
| Qadan, M | 1 |
| Lillemoe, KD | 1 |
| Talele, N | 1 |
| DeLaney, TF | 1 |
| Das, M | 1 |
| Chauhan, VP | 2 |
| Martin, JD | 1 |
| Liu, H | 1 |
| Lacorre, DA | 1 |
| Jain, SR | 1 |
| Kozin, SV | 1 |
| Stylianopoulos, T | 1 |
| Mousa, AS | 1 |
| Han, X | 1 |
| Adstamongkonkul, P | 1 |
| Popović, Z | 1 |
| Huang, P | 1 |
| Bawendi, MG | 1 |
| Kim, S | 1 |
| Toyokawa, H | 1 |
| Yamao, J | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Kwon, AH | 1 |
| Noguchi, R | 1 |
| Yoshiji, H | 1 |
| Ikenaka, Y | 1 |
| Namisaki, T | 1 |
| Kitade, M | 1 |
| Kaji, K | 1 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Yamazaki, M | 1 |
| Tsujimoto, T | 1 |
| Kawaratani, H | 1 |
| Fukui, H | 1 |
| Chehl, N | 1 |
| Gong, Q | 4 |
| Chipitsyna, G | 4 |
| Aziz, T | 1 |
| Yeo, CJ | 3 |
| Arafat, HA | 4 |
| Davis, M | 1 |
| Pezzilli, R | 1 |
| Corinaldesi, R | 1 |
| Morselli-Labate, AM | 1 |
| Diop-Frimpong, B | 1 |
| Krane, S | 1 |
| Pérez-Díaz, I | 1 |
| Guzmán, C | 1 |
| Olivares-Reyes, JA | 1 |
| Ramírez, T | 1 |
| Gutierréz-Reyes, G | 1 |
| Hiriart, M | 1 |
| Robles-Díaz, G | 1 |
| Arnold, SA | 1 |
| Rivera, LB | 1 |
| Carbon, JG | 1 |
| Toombs, JE | 1 |
| Chang, CL | 1 |
| Bradshaw, AD | 1 |
| Brekken, RA | 1 |
| Gray, CF | 1 |
| Haroon, Y | 1 |
| Kamer, E | 1 |
| Anandanadesan, R | 1 |
| Witkiewicz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer[NCT01821729] | Phase 2 | 50 participants (Actual) | Interventional | 2013-07-31 | Active, not recruiting | ||
| Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)[NCT03513198] | 200 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin. (NCT01821729)
Timeframe: At the time of surgery (approximately 4 months after the start of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Arm | 34 |
"To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).~Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be > slice thickness)." (NCT01821729)
Timeframe: From the start of treatment until death or progression, median duration of 17.5 months
| Intervention | Months (Median) |
|---|---|
| Experimental Arm | 17.5 |
2 trials available for losartan and Cancer of Pancreas
| Article | Year |
|---|---|
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Forkhead Transcription Factors; Humans | 2023 |
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil | 2019 |
13 other studies available for losartan and Cancer of Pancreas
| Article | Year |
|---|---|
Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Fatty Acids; Irinote | 2022 |
Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Fatty Acids; Irinote | 2022 |
Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Fatty Acids; Irinote | 2022 |
Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Fatty Acids; Irinote | 2022 |
Combined treatment for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemothera | 2014 |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Deoxycytidine; Drug Synergism; Gemcitabine; Losartan; Male; Mice; | 2009 |
Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells.
Topics: Adenocarcinoma; Angiotensin II; Blotting, Western; Cell Line, Tumor; Chemokine CCL2; Extracellular S | 2009 |
Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Pancreati | 2010 |
Medical therapy for advanced pancreatic cancer: work in progress.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Ag | 2011 |
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.
Topics: Analysis of Variance; Animals; Breast Neoplasms; Carcinoma; Collagen; DNA Primers; Dose-Response Rel | 2011 |
Evidence of an intracellular angiotensin-generating system and non-AT1, non-AT2 binding site in a human pancreatic cell line.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Binding Sites; Carcinoma, Pa | 2011 |
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Extracellular Matrix; Losarta | 2012 |
Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Chemokine CCL2; | 2007 |
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Carcinoma, Pancreatic Du | 2008 |